X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2019 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare AANJANEYA LIFECARE with ALEMBIC PHARMA - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

DR. DATSONS LABS vs ALEMBIC PHARMA - Comparison Results

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    DR. DATSONS LABS ALEMBIC PHARMA DR. DATSONS LABS/
ALEMBIC PHARMA
 
P/E (TTM) x -10.9 18.0 - View Chart
P/BV x 0.2 4.6 3.5% View Chart
Dividend Yield % 0.0 0.7 -  

Financials

 DR. DATSONS LABS   ALEMBIC PHARMA
EQUITY SHARE DATA
    DR. DATSONS LABS
Mar-14
ALEMBIC PHARMA
Mar-18
DR. DATSONS LABS/
ALEMBIC PHARMA
5-Yr Chart
Click to enlarge
High Rs126645 19.5%   
Low Rs31470 6.6%   
Sales per share (Unadj.) Rs133.0166.1 80.1%  
Earnings per share (Unadj.) Rs0.221.9 0.7%  
Cash flow per share (Unadj.) Rs6.627.5 24.0%  
Dividends per share (Unadj.) Rs04.00 0.0%  
Dividend yield (eoy) %00.7 0.0%  
Book value per share (Unadj.) Rs128.8117.8 109.4%  
Shares outstanding (eoy) m31.66188.52 16.8%   
Bonus/Rights/Conversions FCCB--  
Price / Sales ratio x0.63.4 17.5%   
Avg P/E ratio x516.125.5 2,027.5%  
P/CF ratio (eoy) x11.820.3 58.4%  
Price / Book Value ratio x0.64.7 12.8%  
Dividend payout %018.3 0.0%   
Avg Mkt Cap Rs m2,477105,090 2.4%   
No. of employees `000NANA-   
Total wages/salary Rs m566,228 0.9%   
Avg. sales/employee Rs ThNMNM-  
Avg. wages/employee Rs ThNMNM-  
Avg. net profit/employee Rs ThNMNM-  
INCOME DATA
Net Sales Rs m4,21131,308 13.4%  
Other income Rs m7970 111.9%   
Total revenues Rs m4,28931,378 13.7%   
Gross profit Rs m5696,431 8.8%  
Depreciation Rs m2041,055 19.4%   
Interest Rs m43034 1,265.3%   
Profit before tax Rs m135,413 0.2%   
Minority Interest Rs m00-   
Prior Period Items Rs m-2-81 2.2%   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m61,204 0.5%   
Profit after tax Rs m54,128 0.1%  
Gross profit margin %13.520.5 65.7%  
Effective tax rate %48.022.2 216.0%   
Net profit margin %0.113.2 0.9%  
BALANCE SHEET DATA
Current assets Rs m6,85218,247 37.5%   
Current liabilities Rs m6,71111,235 59.7%   
Net working cap to sales %3.322.4 15.0%  
Current ratio x1.01.6 62.9%  
Inventory Days Days16186 188.0%  
Debtors Days Days31861 519.0%  
Net fixed assets Rs m3,67320,035 18.3%   
Share capital Rs m317377 84.0%   
"Free" reserves Rs m3,76121,824 17.2%   
Net worth Rs m4,07822,201 18.4%   
Long term debt Rs m1,6715,000 33.4%   
Total assets Rs m12,63339,411 32.1%  
Interest coverage x1.0160.2 0.6%   
Debt to equity ratio x0.40.2 181.9%  
Sales to assets ratio x0.30.8 42.0%   
Return on assets %3.410.6 32.6%  
Return on equity %0.118.6 0.6%  
Return on capital %7.719.7 38.9%  
Exports to sales %22.946.4 49.3%   
Imports to sales %14.310.5 136.1%   
Exports (fob) Rs m96414,535 6.6%   
Imports (cif) Rs m6023,288 18.3%   
Fx inflow Rs m96414,722 6.5%   
Fx outflow Rs m6077,026 8.6%   
Net fx Rs m3577,696 4.6%   
CASH FLOW
From Operations Rs m1,3453,124 43.0%  
From Investments Rs m-2,256-8,844 25.5%  
From Financial Activity Rs m-1,2005,026 -23.9%  
Net Cashflow Rs m-2,111-693 304.4%  

Share Holding

Indian Promoters % 4.5 74.1 6.1%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 0.0 2.9 -  
FIIs % 1.4 9.1 14.8%  
ADR/GDR % 0.0 0.0 -  
Free float % 94.1 13.9 677.0%  
Shareholders   20,807 49,328 42.2%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare DR. DATSONS LABS With:   WOCKHARDT  J.B.CHEMICALS  MERCK  DIVIS LABORATORIES  FULFORD INDIA  

Compare DR. DATSONS LABS With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Ends Marginally Higher; Realty and Energy Stocks Witness Buying(Closing)

Indian share markets witnessed volatility during closing hours and ended their day marginally higher. Gains were largely seen in the realty sector.

Related Views on News

ALEMBIC PHARMA 2017-18 Annual Report Analysis (Annual Result Update)

Dec 21, 2018 | Updated on Dec 21, 2018

Here's an analysis of the annual report of ALEMBIC PHARMA for 2017-18. It includes a full income statement, balance sheet and cash flow analysis of ALEMBIC PHARMA. Also includes updates on the valuation of ALEMBIC PHARMA.

ALEMBIC PHARMA Announces Quarterly Results (2QFY19); Net Profit Up 61.0% (Quarterly Result Update)

Oct 23, 2018 | Updated on Oct 23, 2018

For the quarter ended September 2018, ALEMBIC PHARMA has posted a net profit of Rs 2 bn (up 61.0% YoY). Sales on the other hand came in at Rs 11 bn (up 42.8% YoY). Read on for a complete analysis of ALEMBIC PHARMA's quarterly results.

MSTC IPO: Should You Bet on This State-Run E-Commerce Player? (IPO)

Mar 13, 2019

Should you subscribe to the IPO of MSPC Limited?

ALEMBIC PHARMA Announces Quarterly Results (1QFY19); Net Profit Up 42.6% (Quarterly Result Update)

Jul 30, 2018 | Updated on Jul 30, 2018

For the quarter ended June 2018, ALEMBIC PHARMA has posted a net profit of Rs 904 m (up 42.6% YoY). Sales on the other hand came in at Rs 9 bn (up 33.1% YoY). Read on for a complete analysis of ALEMBIC PHARMA's quarterly results.

ALEMBIC PHARMA Announces Quarterly Results (4QFY18); Net Profit Up 7.1% (Quarterly Result Update)

Jul 20, 2018 | Updated on Jul 20, 2018

For the quarter ended March 2018, ALEMBIC PHARMA has posted a net profit of Rs 1 bn (up 7.1% YoY). Sales on the other hand came in at Rs 9 bn (up 15.1% YoY). Read on for a complete analysis of ALEMBIC PHARMA's quarterly results.

More Views on News

Most Popular

Are You Ready for the Big Nifty Move in the March Expiry?(Profit Hunter)

Mar 8, 2019

History suggests the Nifty could make a big move in March. Are you prepared to benefit from this opportunity?

Smallcaps Are Rallying and You Need to Make the Most of It Now(Profit Hunter)

Mar 7, 2019

Did you just miss the smallcap rally? Or is there still time to catch up? Read on for answers and more...

The One Sector to Bet on Today as India Grows into a 10 Trillion Dollar Economy(The 5 Minute Wrapup)

Mar 7, 2019

India's defence sector is suddenly under the spotlight. Can this sector ride along India's long-term growth story?

Is it the Right Time to Buy Mid and Small Caps Now?(The 5 Minute Wrapup)

Mar 6, 2019

Mid and Small Caps have underperformed large caps in the past year. Is the tide about to turn?

The Jet Airways Crisis in 6 Charts(Sector Info)

Mar 5, 2019

What happened to Jet Airways, once among top 3 airlines in India? Is it another Kingfisher in the making? Read on...

More

Get the Indian Stock Market's
Most Profitable Ideas

How To Beat Sensex Guide 2019
Get our special report, How to Beat Sensex Nearly 3X Now!
We will never sell or rent your email id.
Please read our Terms

DR. DATSONS LABS SHARE PRICE


May 21, 2015 (Close)

TRACK DR. DATSONS LABS

  • Track your investment in DR. DATSONS LABS with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON DR. DATSONS LABS

DR. DATSONS LABS 5-YR ANALYSIS

COMPARE DR. DATSONS LABS WITH

MARKET STATS